Shaomei Li1, Zhe Zhang1, Hong Tang1, Zhen He1, Yun Gao2, Weiguo Ma2, Yuxi Chang3, Bing Wei3, Jie Ma3, Kangdong Liu4,5, Zhiyong Ma1, Qiming Wang1. 1. Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, 450008, China. 2. Clinical Laboratory, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, 450008, China. 3. Department of Molecular Pathology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, 450008, China. 4. Research Service Office, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, 450008, China. 5. Department of Pathophysiology, School of Basic Medical Science, Zhengzhou University, Zhengzhou, 450001, China.
Abstract
BACKGROUND AND AIMS: Pulmonary Mucoepidermoid carcinoma (MEC) accounts for 0.1-0.2% of all lung cancer. It occurred in the 3-78 years old, and 50% patients younger than 30. MEC has no standard treatment, but recently reports indicated MEC without epidermal growth factor receptor (EGFR) mutations sensitive to gefitinib. OBJECTIVES: To explore a new standard treatment strategy for MEC, after reviewed literature related to MEC, we used Gefitinib to treatment a patient with EGFR-negative MEC, and observe its effects. METHODS: 10-year-old boy was diagnosed with low-grade MEC by bronchial lung biopsy, EGFR gene mutation test was negative. Gefitinib was administered as neoadjuvant therapy at 125 mg daily. RESULTS: The patient underwent right middle lobe, lower lobe resection and mediastinal lymph node dissection. After surgery, the patient had gained weight (5 kg) after 18 days of gefitinib therapy. A CT scan of the chest 1 month after surgical resection showed no recurrence, and followed for 22 months after treatment without tumour recurrence, suggesting that the patient was completely cured. CONCLUSION: Gefitinib has potential to become a standard treatment for pulmonary MEC patients, including pediatric patients. However, the mechanisms need further investigation.
BACKGROUND AND AIMS: Pulmonary Mucoepidermoid carcinoma (MEC) accounts for 0.1-0.2% of all lung cancer. It occurred in the 3-78 years old, and 50% patients younger than 30. MEC has no standard treatment, but recently reports indicated MEC without epidermal growth factor receptor (EGFR) mutations sensitive to gefitinib. OBJECTIVES: To explore a new standard treatment strategy for MEC, after reviewed literature related to MEC, we used Gefitinib to treatment a patient with EGFR-negative MEC, and observe its effects. METHODS: 10-year-old boy was diagnosed with low-grade MEC by bronchial lung biopsy, EGFR gene mutation test was negative. Gefitinib was administered as neoadjuvant therapy at 125 mg daily. RESULTS: The patient underwent right middle lobe, lower lobe resection and mediastinal lymph node dissection. After surgery, the patient had gained weight (5 kg) after 18 days of gefitinib therapy. A CT scan of the chest 1 month after surgical resection showed no recurrence, and followed for 22 months after treatment without tumour recurrence, suggesting that the patient was completely cured. CONCLUSION:Gefitinib has potential to become a standard treatment for pulmonary MECpatients, including pediatric patients. However, the mechanisms need further investigation.
Authors: Lucas R Massoth; Yin P Hung; Dora Dias-Santagata; Maristela Onozato; Nikunj Shah; Eric Severson; Daniel Duncan; Brendan J Gillespie; Nathan F Williams; Jeffrey S Ross; Jo-Anne Vergilio; Shannon K Harkins; Krzysztof Glomski; Valentina Nardi; Lawrence R Zukerberg; Robert P Hasserjian; Abner Louissaint; Erik A Williams Journal: JCO Precis Oncol Date: 2020-02-26